WS #17034
Hims & Hers stock rallied after striking a deal with Eli Lilly to provide access to GLP-1 weight-loss drugs, effectively ending its reliance on compounding medications. This strategic pivot de-risks the company's future revenue model and aligns it with major pharmaceutical manufacturers, potentially improving margins and regulatory standing. The move is viewed positively by investors seeking exposure to the obesity treatment market with lower operational risk.
Hims & Hers GLP-1 Partnership
Hims & Hers stock rallied after striking a deal with Eli Lilly to provide access to GLP-1 weight-loss drugs, effectively ending its reliance on compounding medications. This strategic pivot de-risks the company's future revenue model and aligns it with major pharmaceutical manufacturers, potentially improving margins and regulatory standing. The move is viewed positively by investors seeking exposure to the obesity treatment market with lower operational risk.